Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decrea...
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
George Papanikolaou General Hospital, Thessaloniki, Greece
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
BP Koirala Institute of Health Sciences, Dharan, Sunsari District, Nepal
Department of Anesthesiology and Intensive care of the University of Rome La Sapienza, Rome, Italy
Yuebei People's Hospital, Shaoguan, Guangdong, China
CHU de Nancy, Nancy, France
Kayseri Education and Research Hospital, Kayseri, Turkey
Northwestern Memorial Hospital, Chicago, Illinois, United States
Kyungpook National University Hospital, Daegu, Korea, Republic of
Diskapi Teaching and Research Hospital, Ankara, Altindag, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.